Bent Frandsen
Chief Executive Officer bei EXPRES2ION BIOTECH HOLDING AB
Profil
Bent U.
Frandsen is currently the Chief Executive Officer at ExpreS2ion Biotechnologies ApS, Expres2ion Biotech Holding AB, and Director at Adaptvac ApS.
Previously, he served as the Vice President-Business Development at NsGene A.
He graduated from Copenhagen Business School in 1993.
Aktive Positionen von Bent Frandsen
| Unternehmen | Position | Beginn |
|---|---|---|
| EXPRES2ION BIOTECH HOLDING AB | Chief Executive Officer | 20.12.2019 |
| Adaptvac ApS | Director/Board Member | 01.01.2017 |
ExpreS2ion Biotechnologies ApS
 ExpreS2ion Biotechnologies ApS BiotechnologyHealth Technology ExpreS2ion Biotechnologies ApS operates as a biotechnology company which engages in the field of protein production in Drosophila Schneider-2 cells. Its services include custom proteins and research & development reagents, process development, and feasibility studies. The company was founded by Charlotte Dyring, Martin Roland Jensen, and Willem Adriaan de Jongh in 2009 and is headquartered in Horsholm, Denmark. | Chief Executive Officer | - |
Ehemalige bekannte Positionen von Bent Frandsen
| Unternehmen | Position | Ende |
|---|---|---|
NsGene A/S
 NsGene A/S Pharmaceuticals: MajorHealth Technology NsGene A/S identifies neurotrophic proteins with therapeutic effects in the nervous system. It is a biotechnology company that focuses primarily on neurodegenerative disorders. The firm provides technologies that target protein therapeutics across the blood-brain-barrier and directly to diseased nerve cells. It develops therapeutic products for multiple indications with high medical needs including Alzheimer’s disease, Parkinson's disease, deafness, neuropathic pain, epilepsy, cortico-basal degeneration, and Huntington’s disease. The company was founded by Lars Ulrik Wahlberg and Teit Eliot Johansen in 1999 and is headquartered in Ballerup, Denmark. | Corporate Officer/Principal | - |
Ausbildung von Bent Frandsen
| Copenhagen Business School | Graduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| EXPRES2ION BIOTECH HOLDING AB | Health Technology |
| Private Unternehmen | 3 |
|---|---|
NsGene A/S
NsGene A/S Pharmaceuticals: MajorHealth Technology NsGene A/S identifies neurotrophic proteins with therapeutic effects in the nervous system. It is a biotechnology company that focuses primarily on neurodegenerative disorders. The firm provides technologies that target protein therapeutics across the blood-brain-barrier and directly to diseased nerve cells. It develops therapeutic products for multiple indications with high medical needs including Alzheimer’s disease, Parkinson's disease, deafness, neuropathic pain, epilepsy, cortico-basal degeneration, and Huntington’s disease. The company was founded by Lars Ulrik Wahlberg and Teit Eliot Johansen in 1999 and is headquartered in Ballerup, Denmark. | Health Technology |
ExpreS2ion Biotechnologies ApS
ExpreS2ion Biotechnologies ApS BiotechnologyHealth Technology ExpreS2ion Biotechnologies ApS operates as a biotechnology company which engages in the field of protein production in Drosophila Schneider-2 cells. Its services include custom proteins and research & development reagents, process development, and feasibility studies. The company was founded by Charlotte Dyring, Martin Roland Jensen, and Willem Adriaan de Jongh in 2009 and is headquartered in Horsholm, Denmark. | Health Technology |
| Adaptvac ApS |
